Diabetes and nonalcoholic fatty liver disease: A pathogenic duo

Endocrine Reviews

Volumn 34, Issue 1, 2013, Pages 84-129

  Williams, K H ^a,b   Shackel, N A ^a,b,c   Gorrell, M D ^a,b,c   McLennan, S V ^a,b   Twigg, S M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c CENTENARY INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; BETAINE; BEZAFIBRATE; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SILYMARIN; URSODEOXYCHOLIC ACID;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; BARIATRIC SURGERY; BODY MASS; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ELASTOGRAPHY; ENDOTOXEMIA; EXERCISE; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HEPATITIS C VIRUS; HEREDITY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID METABOLISM; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; NEOPLASMS; RISK FACTORS;

EID: 84874741669     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2012-1009     Document Type: Review

References (426)

1. Musso G, Gambino R, Cassader M, Pagano G 2011 Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43:617-649.
2. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z 2009 Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7:1224-1229, 1229.e1-1229e2.
3. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E 2011 Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link. J Hepatol 54:1020-1029.
4. Targher G, Day CP, Bonora E 2010 Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341-1350.
5. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ 2011 Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 54:753-759.
6. Lo L, McLennan SV, Williams PF, Bonner J, Chowdhury S, McCaughanGW, GorrellMD, YueDK, TwiggSM2011 Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol 55:435-444.
7. Lo L, McLennan SV, Kench JG, McCaughan GW, Bonner J, Williams PF, Gorrell MD, Twigg SM, Diabetes is a progression factor for liver fibrosis and induces cirrhosis in a mouse diet-induced obesity model of NASH. Proc 71st Annual Scientific Sessions of the American Diabetes Association, San Diego, CA, 2011 (Abstract 1682).
8. Defronzo RA 2009 Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795.
9. Reaven GM 2011 Insulin resistance the link between obesity and cardiovascular disease. Med Clin North Am 95: 875-892.
10. de Alwis NM, Day CP 2008 Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48:S104-S112.
11. Starley BQ, Calcagno CJ, Harrison SA 2010 Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820-1832.
12. Milner KL, Chisholm D, George J 2009 The many faces of hepatitis C: liver disease and type 2 diabetes. Hepatology 50:668-670.
13. Virkamäki A, Ueki K, Kahn CR 1999 Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931-943.
14. White MF 1998 The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 182:3-11.
15. Kahn CR 2003 Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes. Exp Diabesity Res 4:169-182.
16. Reaven GM, Hollenbeck CB, Chen YD 1989 Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 32:52-55.
17. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA 1989 Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213.
18. Pocai A, Obici S, Schwartz GJ, Rossetti L 2005 A brainliver circuit regulates glucose homeostasis. Cell Metab 1:53-61.
19. Zsombok A, Smith BN 2009 Plasticity of central autonomic neural circuits in diabetes. Biochim Biophys Acta 1792:423-431.
20. Kawaguchi T, Taniguchi E, Itou M, Sakata M, Sumie S, Sata M 2011 Insulin resistance and chronic liver disease. World J Hepatol 3:99-107.
21. García-Compean D, Jaquez-Quintana JO, Maldonado-GarzaH2009 Hepatogenous diabetes. Current view of an ancient problem. Ann Hepatol 8:13-20.
22. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH 2002 Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 17:677-681.
23. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL 2003 Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38: 50-56.
24. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL 2000 Prevalence of type 2 diabetes mellitus among persons with hepatitis C infection in the United States. Ann Intern Med 133:592-599.
25. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, GuoL, Jacob S, Regenstein FG, ZimmermanR, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP 1999 Association of diabetes mellitus and chronic hepatitisCinfection. Hepatology 29:328-333.
26. Stepanova M, Lam B, Younossi Y, Srishord MK, Younossi ZM2012 Association of hepatitisCwith insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat 19:341-345.
27. Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ 2010 Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 138:932-941.e1-3.
28. Yazicioglu G, Isitan F, Altunbas H, Suleymanlar I, Ozdogan M, Balci MK, Karayalcin U 2004 Insulin resistance in chronic hepatitis C. Int J Clin Pract 58:1020-1022.
29. Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, Smedile A, Ferrannini E, Rizzetto M, Marchesini G, Gastaldelli A, Bugianesi E 2009 Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 50:697-706.
30. Bose SK, Shrivastava S, Meyer K, Ray RB, Ray R 2012 HepatitisCvirus activates themTOR/S6K1signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol 86:6315-6322.
31. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M2004 Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signalling 3. Am J Pathol 165:1499-1508.
32. Lecube A, Hernández C, Genescá J, Simó R 2006 Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitisCpatients: a case-control study. Diabetes Care 29:1096-1101.
33. Deng L, Shoji I, Ogawa W, Kaneda S, Soga T, Jiang DP, Ide YH, Hotta H 2011 Hepatitis C virus infection promotes hepatic glucogenogenesis through an NS5A-mediated, FoxO1-dependent pathway. J Virol 85:8556-8568.
34. YounossiZM, McCullough AJ 2009 Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 29:3-12.
35. Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, Lupi R, Del Guerra S, Bugliani M, Torri S, Del Prato S, Mosca F, Filipponi F, Marchetti P 2005 Hepatitis Cvirus infection and human pancreaticβ-cell dysfunction. Diabetes Care 28:940-941.
36. Brandman D, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, Terrault NA 2011 Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 17:1380-1386.
37. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M 2011 Use of HOMA-IR in hepatitis C. J Viral Hepat 18:675-684.
38. YounossiZM, McCullough AJ, OngJP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R 2004 Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 38:705-709.
39. Hü bscher SG 2011 Steatosis and fibrosis progression in patients with recurrent hepatitis C infection: complex interactions providing diagnostic and therapeutic challenges. Liver Transpl 17:1374-1379.
40. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T 2011 Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9:428-433; quiz e50.
41. Petta S, Cammá C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxì A 2008 Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 103:1136-1144.
42. Powell EE, Jonsson JR, Clouston AD 2010 Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis 28:186-191.
43. Ludwig J, Viggiano TR, McGill DB, Oh BJ 1980 Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438.
44. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ 1999 Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419.
45. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR 1999 Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474.
46. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321.
47. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z 2011 Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53:1874-1882.
48. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR 2011 Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:810-820.
49. Dorn C, Riener MO, Kirovski G, Saugspier M, Steib K, Weiss TS, Gä bele E, Kristiansen G, Hartmann A, Hellerbrand C 2010 Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol 3:505-514.
50. Hebbard L, George J 2011 Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 8:35-44.
51. Adams L 2010 Transient elastography in nonalcoholic fatty liver disease: making sense of echoes. Hepatology 51: 370-372.
52. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, HobbsHH2004 Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395.
53. Rinella ME 2011 Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease. Hepatology 54:1118-1120.
54. Chalasani N, Younossi Z, Lavine JE, DiehlAM, BruntEM, Cusi K, Charlton M, Sanyal AJ 2012 The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 107:811-826.
55. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA 2011 Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: prospective study. Gastroenterology 140:124-131.
56. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA 2011 Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249-1253.
57. Rafiq N, Bai C, Fang Y, SrishordM, McCullough A, Gramlich T, Younossi ZM 2009 Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7:234-238.
58. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL 2010 Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59: 969-974.
59. Angulo P 2010 Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance. Hepatology 51:373-375.
60. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S 2006 Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873.
61. Dixon JB, Bhathal PS, O'Brien PE 2001 Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91-100.
62. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP 2007 The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846-854.
63. Adams LA, Sanderson S, Lindor KD, Angulo P 2005 The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42:132-138.
64. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J 2011 Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 60:313-326.
65. Wang JK, Feng ZW, Li YC, Li QY, Tao XY 2012 Association of tumour necrosis factor-α gene promoter polymorphism at sites-308 and-238 with non-alcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol 27: 670-676.
66. Adams LA 2011 Biomarkers of liver fibrosis. J Gastroenterol Hepatol 26:802-809.
67. Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A 2011 A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 21:431-439.
68. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ 2002 The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745-750.
69. Williamson RM, Perry E, Glancy S, Marshall I, Gray C, Nee LD, Hayes PC, Forbes S, Frier BM, Johnston GI, Lee AJ, Reynolds RM, Price JF, Strachan MWJ 2011 The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra-and interobserver variability and comparison with magnetic resonance spectroscopy. Clin Radiol 66: 434-439.
70. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E 2010 Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 53:713-718.
71. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF 2011 Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 31: 700-706.
72. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL 2012 Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366:1567-1576.
73. Angulo P, Keach JC, Batts KP, Lindor KD 1999 Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356-1362.
74. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, Chan AW, Choi PC, Chim AM, Lau JY, Chan FK, Sung JJ, Chan HL 2011 High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 60: 829-836.
75. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR, Australian Diabetes Society, Australian Diabetes Educators Association 2007 Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 186:461-465.
76. Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, Park CY, Oh KW, Sung KC, Kim BI 2010 Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 105:2389-2395.
77. Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, SoWY, Cheng AY, Tong PC, Chan FK, Sung JJ, Chan HL 2006 Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 24: 1215-1222.
78. Manchanayake J, Chitturi S, Nolan C, Farrell GC 2011 Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 26:510-516.
79. Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K 2011 Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol 26:517-522.
80. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K 2012 Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35:873-878.
81. Sung KC, Kim SH 2011 Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 96:1093-1097.
82. Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW 2011 Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 34:727-729.
83. Cusi K 2012 Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142:711-725.e6.
84. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G 2006 Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29:1325-1330.
85. Sö derberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R 2010 Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51:595-602.
86. Lee YJ, Shim JY, MoonBS, Shin YH, Jung DH, Lee JH, Lee HR 2012 The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 57:196-203.
87. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G 2007 Prevalence of nonalcoholic fatty liver disease and its assocation with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212-1218.
88. Lautamäki R, Borra R, Iozzo P, Komu M, Lehtimäki T, Salmi M, Jalkanen S, Airaksinen KE, Knuuti J, Parkkola R, Nuutila P 2006 Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 291: E282-E290.
89. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, AdamsLA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J 2011 The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54:1208-1216.
90. The Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J 2010 Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215-2222.
91. McKimmie RL, Daniel KR, Carr JJ, Bowden DW, Freedman BI, Register TC, Hsu FC, Lohman KK, Weinberg RB, Wagenknecht LE 2008 Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 103: 3029-3035.
92. Poanta LI, Albu A, Fodor D 2011 Association between fatty liver disease and carotid atherosclerosis in patients with uncomplicated type 2 diabetes mellitus. MedUltrason 13:215-219.
93. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, Schminke U, Kessler C, John U 2005 Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 11: 1848-1853.
94. Catalano D, Trovato GM, Martines GF, Pirri C, Trovato FM 2011 Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate. Hepatol Int 5:822-829.
95. Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E 2012 Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver. Diabet Med 29:220-226.
96. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M 2010 Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 5:2166-2171.
97. Houlihan DD, Armstrong MJ, Davidov Y, Hodson J, Nightingale P, Rowe IA, Paris S, Gunson BK, Bramhall SB, Mutimer DJ, Neuberger JM, Newsome PN 2011 Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens. Liver Transpl 17:1292-1298.
98. Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, Zenari L, Bonora E 2010 Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 53:1341-1348.
99. de Lédinghen V, Vergniol J, Gonzalez C, Foucher J, Maury E, Chemineau L, Villars S, Gin H, Rigalleau V 2012 Screening for liver fibrosis by using FibroScan and FibroTest in patients with diabetes. Dig Liver Dis 44:413-418.
100. Donadon V, Balbi M, Valent F, Avogaro A 2010 Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 16: 3025-3032.
101. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL 2008 Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systemic review and meta-analysis. JAMA 300:2754-2764.
102. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC 2012 Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 107: 46-52.
103. El-Serag HB, Hampel H, Javadi F 2006 The association between diabetes and hepatocellular carcinoma: a systemic review of epidemiological evidence. Clin Gastroenterol Hepatol 4:369-380.
104. Noto H, Osame K, Sasazuki T, Noda M 2010 Substantially increased risk of cancer in patients with diabetes mellitus: a systemic review and meta-analysis of epidemiological evidence in Japan. J Diabetes Complications 24: 345-353.
105. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J 2011 Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364: 829-841.
106. Tilg H, DiehlAM2011 NAFLD and extrahepatic cancers: have a look at the colon. Gut 60:745-746.
107. Sahathevan R, Brodtmann A, DonnanGA2012 Dementia, stroke, and vascular risk factors: a review. Int J Stroke 7:61-73.
108. Li L, Wang Y, Yan J, Chen Y, Zhou R, Yi X, Shi Q, Zhou H, The Chongqing Aging Study Group 2012 Clinical predictors of cognitive decline in patients with mild cognitive impairment: the Chongqing Aging Study. J Neurol 259: 1303-1311.
109. Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres ML, Civera M, Olmo JA, Ortega J, Martinez-Valls J, Serra MA, Cassinello N, Wassel A, Jordá E, Montoliu C 2012 Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis 27:51-58.
110. Schuetz P, Castro P, Shapiro NI 2011 Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care 34:771-778.
111. Nseir W, Taha H, Khateeb J, Grosovski M, Assy N 2011 fatty liver is associated with recurrent bacterial infections independent of metabolic syndrome. Dig Dis Sci 56:3328-3334.
112. Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, Barbieri E, TargherG2012 Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35:389-395.
113. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S 2006 Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40:949-955.
114. Larter CZ, Yeh MM 2008 Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23:1635-1648.
115. Anstee QM, Goldin RD 2006 Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87:1-16.
116. Ariz U, Mato JM, Lu SC, Martínez Chantar ML 2010 Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new. Methods Mol Biol 593:109-136.
117. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA 2008 Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and highfructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295:G987-G995.
118. Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martínez-Chantar ML 2009 Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 41:969-976.
119. Rinella ME, Green RM 2004 The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40:47-51.
120. de Oliveira CP, de Lima VM, Simplicio FI, Soriano FG, de Mello ES, de Souza HP, Alves VA, Laurindo FR, Carrilho FJ, de OliveiraMG2008 Prevention and reversion of nonalcoholic steatohepatitis in ob/ob mice by S-nitroso-Nacetylcysteine treatment. J Am Coll Nutr 27:299-305.
121. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF 2004 Obese and diabetic db/db mice develop marked liver fibrosis in a model of non-alcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastroenterol Liver Physiol 287: G1035-G1043.
122. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Mü ller C, Carling D, Kahn BB 2002 Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339-343.
123. Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC, YehMM, FarrellGC2006 Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys ResCommun342:1152-1159.
124. Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY, Williams J, Clyne M, Nolan CJ, Farrell GC 2009 Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 24:1658-1668.
125. Zhou H, Saito S, Piao G, Liu ZP, Wang J, Horimoto K, ChenL2011 Network screening of Goto-Kakizaki rat liver microarray data during diabetic progression. BMC Syst Biol 5 Suppl 1:S16.
126. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y 2011 Dietinduced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60:1246-1257.
127. Matafome P, Louro T, Rodrigues L, Crisó stomo J, Nunes E, Amaral C, Monteiro P, Cipriano A, Seiça R 2011 Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 27:54-62.
128. Matafome P, Nunes E, Louro T, Amaral C, Crisó stomo J, Rodrigues L, Moedas AR, Monteiro P, Cipriano A, Seiça R 2009 A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. Naunyn Schmiedebergs Arch Pharmacol 379:241-251.
129. Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC 2012 Peroxisome proliferatoractivated receptor-α agonist, 643, improves metabolic indices, steatosis and ballooning in diabetic miceWy14 with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 27: 341-350.
130. Duval C, Thissen U, Keshtkar S, Accart B, Stienstra R, Boekschoten MV, Roskams T, Kersten S, Mü llerM2010 Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes 59:3181-3191.
131. Gaemers IC, Stallen JM, Kunne C, Wallner C, van Werven J, Nederveen A, Lamers WH 2011 Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. Biochim Biophys Acta 1812:447-458.
132. Sasaki Y, Suzuki W, Shimada T, Iizuka S, Nakamura S, Nagata M, Fujimoto M, Tsuneyama K, Hokao R, Miyamoto K, AburadaM2009 Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice. Life Sci 85: 490-498.
133. DeFronzo RA, Ferrannini E 1991 Insulin resistance. Amultifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194.
134. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ, European Liver Fibrosis Group 2004 Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127:1704-1713.
135. Klein T, The dipeptidyl peptidase 4 inhibitor linagliptin is an effective therapeutic for metabolic liver disease in several rodent models of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Proc 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2011 p 369A (Abstract 20).
136. Ali R, Cusi K 2009 New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41:265-278.
137. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jä rvinen H, Svegliati-Baroni G 2010 From the metabolic syndrome toNAFLDor vice versa. Dig Liver Dis 42:320-330.
138. Larter CZ, Chitturi S, Heydet D, Farrell GC 2010 A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 25:672-690.
139. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, Shiehmorteza M, Yokoo T, Chavez A, Middleton MS, Sirlin CB 2009 Heritability of nonalcoholic fatty liver disease. Gastroenterology 136:1585-1592.
140. Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR 2006 Familial aggregation of insulin resistance in firstdegree relatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4:1162-1169.
141. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J 2002 NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379.
142. Bonnefond A, Froguel P, Vaxillaire M 2010 The emerging genetics of type 2 diabetes. Trends Mol Med 16:407-416.
143. Anstee QM, Daly AK, Day CP 2011 Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim Biophys Acta 1812:1557-1566.
144. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P 2007 A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885.
145. Ono M, Okamoto N, Saibara T 2010 The latest idea in NAFLD/NASH pathogenesis. Clin J Gastroenterol 3:263-270.
146. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O'Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS, Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB 2011 Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324.
147. Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Kö nigsrainer I, Kö nigsrainer A, Schick F, Fritsche A, Hä ringHU, StefanN2009 Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58:2616-2623.
148. Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N 2012 Ethnicity and nonalcoholic fatty liver disease. Hepatology 55:769-780.
149. Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P, Bouillet B, Brindisi MC, Robin I, Gambert P, Verges B, Cercueil JP, Hillon P 2011 PNPLA3 polymorphism influ-ences liver fibrosis in unselected patients with type 2 diabetes. Liver Int 31:1332-1336.
150. Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, Fontanini E, Fornasiere E, Bignulin S, Fumolo E, Bignulin E, Pirisi M, Toniutto P 2011PNPLA3rs 738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 31: 1137-114.
151. Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN 2010 PNPLA3 variants specifically confer increased risk for histological nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52:904-912.
152. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI 2010 ApolipoproteinC3gene variants in nonalcoholic fatty liver disease. N Engl J Med 362:1082-1089.
153. Sookoian S, Castanõ GO, Burguenõ AL, Gianotti TF, Rosselli MS, Pirola CJ 2010 The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics 20:1-8.
154. Bernard S, Touzet S, Personne I, Lapras V, Bondon PJ, Berthezéne F, Moulin P 2000 Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 43:995-999.
155. NamikawaC, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H, Onishi S 2004 Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 40:781-786.
156. Dong H, Wang J, Li C, Hirose A, Nozaki Y, Takahashi M, Ono M, Akisawa N, Iwasaki S, Saibara T, Onishi S 2007 The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol 46: 915-920.
157. Song J, da Costa KA, Fischer LM, Kohlmeier M, Kwock L, Wang S, Zeisel SH 2005 Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 19:1266-1271.
158. Tang H, Wang XX, Zhao SG, Wang JJ, Zhang C, Lu W, Li HY, Wen QS 2011 Association between the G175a and rs12325817 polymorphisms in the phosphatidylethanolamine N-methyltransferase gene and susceptibility to nonalcoholic fatty liver disease. World Chin J Digestol 19: 3035-3039.
159. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K 2007 Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 46:1104-1110.
160. Carulli L, Canedi I, Rondinella S, Lombardini S, Ganazzi D, Fargion S, De Palma M, Lonardo A, Ricchi M, Bertolotti M, Carulli N, Loria P 2009 Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis 41:823-828.
161. Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, Dongiovanni P, Fracanzani AL, Alterio A, Roviaro G, Daly AK, Fargion S, Day CP 2011 The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 55:1409-1414.
162. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH 2011 Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53:467-474.
163. Sentinelli F, Romeo S, Maglio C, Incani M, Burza MA, Scano F, Coccia F, Cossu E, Leonetti F, Baroni MG 2011 Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis 10:93.
164. van Hoek M, van Herpt TW, Dehghan A, Hofman A, Lieverse AG, van Duijn CM, Witteman JC, Sijbrands EJ 2011 Association of anAPOC3promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons. Diabetologia 54:1360-1367.
165. Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK 2012 The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 56:448-454.
166. Möllsten A, Marklund SL, WessmanM, SvenssonM, Forsblom C, Parkkonen M, Brismar K, Groop PH, Dahlquist G 2007 A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes 56:265-269.
167. Petrovic MG, Cilensek I, Petrovic D 2008 Manganese superoxide dismutase gene polymorphism (V16A) is associated with diabetic retinopathy in Slovene (Caucasians) type 2 diabetes patients. Dis Markers 24:59-64.
168. Tian C, Fang S, Du X, Jia C 2011 Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia 54:803-811.
169. Rubin D, Helwig U, Pfeuffer M, Schreiber S, Boeing H, Fisher E, Pfeiffer A, Freitag-Wolf S, Foelsch UR, Doering F, Schrezenmeir J 2006 A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. J Hum Genet 51:567-574.
170. Musso G, Gambino R, Cassader M 2010 Lipoprotein metabolism mediates the association of MTP polymorphism with β-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. J Nutr Biochem 21:834-840.
171. Feng R, Li Y, Zhao D, Wang C, Niu Y, Sun C 2009 Lack of association between TNF 238G/A polymorphism and type 2 diabetes: a meta-analysis. Acta Diabetol 46:339-343.
172. Feng RN, Zhao C, Sun CH, Li Y 2011 Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes. PLoS ONE 6:e18480.
173. Feng RN, Li Y, Sun CH 2009 TNF308 G/A polymorphism and type 1 diabetes: a meta-analysis. Diabetes Res Clin Pract 85:e4-e7.
174. Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V 2012 Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. AnnMed 44:29-40 Endocrine Reviews, February 2013, 34(1):84-129 edrv.endojournals.org 119.
175. Yazýcý D, Özben B, Yavuz D, Deyneli O, Aydýn H, Tarcin Ö, Akalýn S 2011 Epicardial adipose tissue thickness in type 1 diabetic patients. Endocrine 40:250-255.
176. Danielson KK, Drum ML, Estrada CL, Lipton RB 2010 Racial and ethnic differences in an estimated measure of insulin resistance among individuals with type 1 diabetes. Diabetes Care 33:614-619.
177. Jou J, Choi SS, Diehl AM 2008 Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28:370-379.
178. Sheth SG, Gordon FD, Chopra S 1997 Nonalcoholic steatohepatitis. Ann Intern Med 126:137-145.
179. Neuschwander-Tetri BA 2010 Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52:774-788.
180. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, Finch J, Gastaldelli A, Harrison S, Tio F, Cusi K 2012 Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 55:1389-1397.
181. Brown MS, Goldstein JL 2008 Selective vs total insulin resistance: a pathogenic paradox. Cell Metab 7:95-96.
182. Li S, Brown MS, Goldstein JL 2010 Bifurcation of insulin signaling pathway in rat liver:mTORC1required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 107:3441-3446.
183. Shimomura I, Bashmakov Y, Horton JD 1999 Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274: 30028-30032.
184. Samuel VT, Petersen KF, Shulman GI 2010 Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375: 2267-2277.
185. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL 1999 Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocininduced diabetes. Proc Natl Acad Sci USA 96:13656-13661.
186. Horton JD, Goldstein JL, Brown MS 2002 SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125-1131.
187. Lee YS, Sohn DH, Han D, Lee HW, Seong RH, Kim JB 2007 Chromatin remodeling complex interacts with ADD1/SREBP1c to mediate insulin-dependent regulation of gene expression. Mol Cell Biol 27:438-452.
188. Sajan MP, Standaert ML, Rivas J, Miura A, Kanoh Y, Soto J, Taniguchi CM, Kahn CR, Farese RV 2009 Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor κB (NFκB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance. Diabetologia 52:1197-1207.
189. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL 1997 Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99:846-854.
190. Ferré P, Foufelle F 2010 Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12:83-92.
191. Harrison SA, Day CP 2007 Recent advances in clinical practice: the role of lifestyle modification in NAFLD. Gut 56:1760-1769.
192. Adeli K, Theriault A 1992 Insulin modulation of human apolipoprotein-B messenger RNA translation-studies in an in vitro cell-free system fromHEPG2cells. Biochem Cell Biol 70:1301-1312.
193. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L 2009 Molecular mechanisms involved in NAFLD progression. J Mol Med 87:679-695.
194. Cazanave SC, Gores GJ 2010 Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 5:71-85.
195. Wei Y, Wang D, Topczewski F, Pagliassotti MJ 2006 Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 291:E275-E281.
196. Liu Y, Qiu de K, Ma X 2012 Liver X receptors bridge hepatic lipid metabolism and inflammation. J Dig Dis 13: 69-74.
197. Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu M, Nakajima T, Nishizawa T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Nakayama J, Tanaka E, AoyamaT2010 Down-regulation of SREBP-1c is associated with the development of burned-out NASH. J Hepatol 53:724-731.
198. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ 2005 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343-1351.
199. Sunny NE, Parks EJ, Browning JD, Burgess SC 2011 Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 14:804-810.
200. Puri P, WiestMM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, Sanyal AJ 2009 The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50:1827-1838.
201. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ 2007 A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46:1081-1090.
202. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC 2011 Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141:1393-1403, 1403.e1-e5.
203. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel VT, Shulman GI 2011 Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 108:16381-16385.
204. Gorden DL, Ivanova PT, Myers DS, McIntyre JO, VanSaunMN, Wright JK, Matrisian LM, BrownHA2011 Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS ONE 6:e22775.
205. Lyn-Cook Jr LE, Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H, de la Monte SM 120 Williams et al. Diabetes and NAFLD: A Pathogenic Duo Endocrine Reviews, February 2013, 34(1):84-129 2009 Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and nonalcoholic steatohepatitis. J Alzheimers Dis 16:715-729.
206. Garcia-Ruiz C, Marí M, Colell A, Morales A, Fernandez-Checa JC 2011 Metabolic therapy: lessons from liver diseases. Curr Pharm Des 17:3933-3944.
207. Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP 2012 Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 23:365-371.
208. Farrell GC, van Rooyen D, Gan L, Chitturi S 2012 NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 6:149-171.
209. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV, Nash Clinical Research Network 2010 Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52:913-924.
210. Musso G, Gambino R, Cassader M 2010 Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 11:430-445.
211. Leclercq IA, Farrell GC, Sempoux C, dela Peña A, Horsmans Y 2004 Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 41:926-934.
212. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ 2006 JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43:163-172.
213. Tacke F, Luedde T, TrautweinC2009 Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 36:4-12.
214. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH 2009 Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51:371-379.
215. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA 2009 Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 49:809-820.
216. Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Paik YH, Miura K, Kodama Y 2011 Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res 41:683-686.
217. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T 2006 Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55:415-424.
218. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, Gores GJ 2003 Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38:1188-1198.
219. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW, Choi AM 2011 Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrialDNAmediated by the NALP3 inflammasome. Nat Immunol 12:222-230.
220. Neuschwander-Tetri BA 2010 Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr Gastroenterol Rep 12:49-56.
221. Lockman KA, Baren JP, Pemberton CJ, Baghdadi H, Burgess KE, Plevris-Papaioannou N, Lee P, Howie F, Beckett G, Pryde A, Jaap AJ, Hayes PC, Filippi C, Plevris JN 2012 Oxidative stress rather than triglyceride accumulation is a determinant of mitochondrial dysfunction in in vitro models of hepatic cellular steatosis. Liver Int 32:1079-1092.
222. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J 2004 Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 40:46-54.
223. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H 2004 Adiponectin protects LPSinduced liver injury through modulation of TNF-α in KK-Ay obese mice. Hepatology 40:177-184.
224. Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafiadis G, Assimakopoulos SF, Asimakopoulos S, Labropoulou-Karatza C 2008 Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg 71:355-360.
225. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL 1999 Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 104: 447-457.
226. Xi L, Xiao C, Bandsma RH, Naples M, Adeli K, Lewis GF 2011 C-Reactive protein impairs hepatic insulin sensitivity and insulin signaling in rats: role of mitogen-activated protein kinases. Hepatology 53:127-135.
227. Chen A, Zheng S 2008 Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-κB and ERK signalling. Br J Pharmacol 153:557-567.
228. Jiang MD, Zheng SM, Xu H, Zeng WZ, Zhang Y, Sun HP, Wang YX, Qin JP, Wu XL 2008 An experimental study of extracellular signal-regulated kinase and its interventional treatments in hepatic fibrosis. Hepatobiliary Pancreat Dis Int 7:51-57.
229. Gao R, Ball DK, Perbal B, Brigstock DR 2004 Connective tissue growth factor induces c-fos gene activation and cell proliferation through p44/42 MAP kinase in primary rat hepatic stellate cells. J Hepatol 40:431-438.
230. Handy JA, Fu PP, Kumar P, Mells JE, Sharma S, Saxena NK, AnaniaFA2011 Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J 440:385-395.
231. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Häring HU 2008 Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168: 1609-1616.
232. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI 2002 Leptin reverses insulin resistance and hepatic ste-Endocrine Reviews, February 2013, 34(1):84-129 edrv.endojournals.org 121 atosis in patients with severe lipodystrophy. J Clin Invest 109:1345-1350.
233. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI 2004 Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345-32353.
234. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K 2003 A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52:2461-2474.
235. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E 2007 Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. AmJ Physiol EndocrinolMetab292:E1775-E1781.
236. Goh SY, Cooper ME 2008 The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93:1143-1152.
237. Kimura Y, HyogoH, Yamagishi S, TakeuchiM, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K 2010 Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 45: 750-757.
238. Guimarães EL, Empsen C, Geerts A, van Grunsven LA 2010 Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol 52:389-397.
239. Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K 2004 Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA 101:7281-7286.
240. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C 2006 Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 55:2159-2170.
241. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P 2001 High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34:738-744.
242. Lin J, Chen A 2011 Curcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2. Mol Cell Endocrinol 333:160-171.
243. Könner AC, Brüning JC 2011 Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab 22:16-23.
244. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferriéres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R 2007 Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761-1772.
245. Amyot J, Semache M, Ferdaoussi M, Fontés G, Poitout V 2012 Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-like receptor-4 and NF-κB signalling. PLoS ONE 7:e36200.
246. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, Fitzgerald KA, Hwang DH 2004 Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 279:16971-16979.
247. Schaeffler A, Gross P, Buettner R, Bollheimer C, Buechler C, Neumeier M, Kopp A, Schoelmerich J, Falk W 2009 Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-κB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 126:233-245.
248. MancoM, Putignani L, Bottazzo GF 2010 Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31: 817-844.
249. Serino M, Luche E, Gres S, Baylac A, Bergé M, Cenac C, Waget A, Klopp P, Iacovoni J, Klopp C, Mariette J, Bouchez O, Lluch J, Ouarné F, Monsan P, Valet P, Roques C, Amar J, Bouloumié A, Théodorou V, Burcelin R 2012 Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 61:543-553.
250. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S 2007 Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740-E747.
251. Cornell RP 1980 Mechanisms of acute hyperinsulinemia after Kupffer cell phagocytosis. Am J Physiol 238:E276-E283.
252. ByrneMM, Pluntke K, Wank U, Schirra J, Arnold R, Göke B, Katschinski M 1998 Inhibitory effects of hyperglycaemia on fed jejunal motility: potential role of hyperinsulinaemia. Eur J Clin Invest 28:72-78.
253. Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, Gasbarrini G 2002 Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology 49:1582-1586.
254. Erridge C, Attina T, Spickett CM, Webb DJ 2007 A highfat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. AmJ Clin Nutr 86:1286-1292.
255. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J 2008 Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48:449-457.
256. IbrahimMM 2010 Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 11: 11-18.
257. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, O'Donnell CJ, Fox CS 2010 Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 51:1979-1987.
258. Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, Consonni D, Fatta E, Lombardi R, Marchesini G, Fargion S 2011 Risk of nonalcoholic steatohepatitis and 122 Williams et al. Diabetes and NAFLD: A Pathogenic Duo Endocrine Reviews, February 2013, 34(1):84-129 fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol 54:1244-1249.
259. Machado MV, Cortez-Pinto H 2011 No need for a large belly to have NASH. J Hepatol 54:1090-1093.
260. Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB 2010 Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care 33:2477-2483.
261. Tappy L, LêKA 2010 Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 90:23-46.
262. Steinbrecher A, Morimoto Y, Heak S, Ollberding NJ, Geller KS, Grandinetti A, Kolonel LN, Maskarinec G 2011 The preventable proportion of type 2 diabetes by ethnicity: the multiethnic cohort. Ann Epidemiol 21:526-535.
263. Voulgari C, Katsilambros N, Tentolouris N 2011 Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 60:1456-1464.
264. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA 2012 Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55: 429-436.
265. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB 2011 Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 106:460-468; quiz 469.
266. Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G 2011 Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301:G825-G834.
267. Kayaniyil S, Vieth R, Harris SB, Retnakaran R, Knight JA, Gerstein HC, Perkins BA, Zinman B, Hanley AJ 2011 Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab 96:168-175.
268. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, Arcaro G 2007 Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17:517-524.
269. Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG 2011 Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitaminDlevels in an adult population with normal serum liver enzymes. BMC Med 9:85.
270. Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M, Leandro G, Arvaniti V, Germani G, Patch D, Calvaruso V, Mikhailidis DP, Dhillon AP, Burroughs AK 2011 Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 31:730-739.
271. Ford ES, Cogswell ME 1999 Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 22:1978-1983.
272. Sos BC, Harris C, Nordstrom SM, Tran JL, Balázs M, Caplazi P, Febbraio M, ApplegateMA, Wagner KU, Weiss EJ 2011 Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest 121:1412-1423.
273. García-Galiano D, Sánchez-Garrido MA, Espejo I, Montero JL, Costán G, Marchal T, Membrives A, Gallardo-Valverde JM, Muñoz-Castañeda JR, Arévalo E, DelaMata M, Muntané J 2007 IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 17:493-503.
274. Vardatsikos G, Sahu A, Srivastava AK 2009 The insulinlike growth factor family: molecular mechanisms, redox regulation, and clinical implications. Antioxid Redox Signal 11:1165-1190.
275. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ 2002 Circulating concentrations of insulin-like growth factor-1 and development of glucose intolerance: a prospective observational study. Lancet 359:1740-1745.
276. Colak Y, Senates E, Ozturk O, Yilmaz Y, Zemheri E, Yilmaz Enc F, Ulasoglu C, Aksaray S, Bozbeyoglu SG, Kiziltas S, Kurdas OO, Tuncer I 2012 Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 24:255-261.
277. Hsueh WA, Wyne K 2011 Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 13:224-237.
278. Vinik AI, Maser RE, Ziegler D 2011 Autonomic imbalance: prophet of doom or scope for hope? Diabet Med 28:643-651.
279. Polyzos SA, Kountouras J, Zafeiriadou E, Patsiaoura K, Katsiki E, Deretzi G, Zavos C, Tsarouchas G, Rakitzi P, Slavakis A 2011 Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst 12:498-503.
280. Byrne TJ, Parish JM, Somers V, Aqel BA, Rakela J 2012 Evidence for liver injury in the setting of obstructive sleep apnea. Ann Hepatol 11:228-231.
281. Aron-Wisnewsky J, Minville C, Tordjman J, Lévy P, Bouillot JL, Basdevant A, Bedossa P, Clément K, Pépin JL 2012 Chronic intermittent hypoxia is a major trigger for nonalcoholic fatty liver disease in morbid obese. J Hepatol 56:225-233.
282. Ronksley PE, Hemmelgarn BR, Heitman SJ, Hanly PJ, Faris PD, Quan H, Tsai WH 2009 Obstructive sleep apnoea is associated with diabetes in sleepy subjects. Thorax 64:834-839.
283. Day CP, Saksena S 2002 Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 17(Suppl 3):S377-S384.
284. Jamieson HA, Cogger VC, Twigg SM, McLennan SV, Warren A, Cheluvappa R, Hilmer SN, Fraser R, de Cabo R, Le Couteur DG 2007 Alterations in liver sinusoidal endothelium in baboon model of type 1 diabetes. Diabetologia 50:1969-1976.
285. Bernuau D, Guillot R, Durand-Schneider AM, Poussier P, Moreau A, Feldmann G 1985 Liver perisinusoidal fibrosis in BB rats with or without overt diabetes. Am J Pathol 120:38-45.
286. Latry P, Bioulac-Sage P, Echinard E, Gin H, Boussarie L, Grimaud JA, Balabaud C 1987 Perisinusoidal fibrosis and basement membrane-like material in the livers of diabetic patients. Hum Pathol 18:775-780.
287. Harrison SA, Brunt EM, Goodman ZD, Di Bisceglie AM 2006 Diabetic hepatosclerosis: diabetic microangiopathy of the liver. Arch Pathol Lab Med 130:27-32.
288. McGill M, Molyneaux L, Twigg SM, Yue DK 2008 The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications 22:18-23.
289. Obika M, Noguchi H 2012 Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012: 145754.
290. Smith BW, Adams LA 2011 Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7:456-465.
291. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL 2005 Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288: E462-E468.
292. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T 2007 The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102:2708-2715.
293. Kawasaki S, Hasegawa O, Satoh S, Numata K, TerauchiY 2010 Sonographic assessment of fatty liver infiltration using the measurement of para-and perirenal fat thickness. J Clin Ultrasound 38:470-474.
294. Liu KH, Chan YL, Chan JCN, Chan WB, Kong WL 2006 Mesenteric fat thickness as an independent determinant of fatty liver. Int J Obes 30:787-793.
295. Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A 2010 The role of lipopolysaccharide/tolllike receptor 4 signaling in chronic liver diseases. Hepatol Int 4:659-672.
296. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S 2008 Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48:792-798.
297. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ 2003 Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normalALTvalues. Hepatology 37:1286-1292.
298. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G 2002 Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1-10.
299. Shlomai A, Kariv R, Leshno M, Beth-or A, Sheinberg B, HalpernZ2010 Large-scale population analysis reveals an extremely low threshold for 'non-healthy' alanine aminotransferase that predicts diabetes mellitus. J Gastroenterol Hepatol 25:1687-1691.
300. Kang HS, UmSH, Seo YS, AnH, Lee KG, Hyun JJ, Kim ES, Park SC, KeumB, Kim JH, Yim HJ, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS 2011 Healthy range for serum ALT and the clinical significance of "unhealthy" normal ALT levels in the Korean population. J Gastroenterol Hepatol 26:292-299.
301. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T 2005 Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128:1898-1906.
302. Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H 2005 Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 15: 497-501.
303. Vuppalanchi R, Unalp A, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, Tonascia J, Chalasani N 2009 Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7:481-486.
304. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, de LédinghenV2010 Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51:454-462.
305. Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V 2010 Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51:828-835.
306. Petta S, Di Marco V, CammáC, Butera G, Cabibi D, Craxì A 2011 Reliability of liver stiffness measurement in nonalcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 33:1350-1360.
307. Myers R, Pomier-Layrargues G, Duarte-Rojo A, Wong D, Beaton M, Levstik M, Kirsch R, Pollett A, Crotty P, Sasso M, Landau M, Elkashab M 2011 Performance of the Fibroscan XL probe for liver stiffness measurement in obese patients: a multicentre validation study. Canadian Digestive Diseases Week. Vancouver, British Colombia (Abstract A039).
308. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Beaton M, Levstik M, Duarte-Rojo A, Wong D, Crotty P, ElkashabM2012 Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 56:564-570.
309. de Lédinghen V, WongVW, Vergniol J, WongGL, Foucher J, Chu SH, Le Bail B, Choi PC, Chermak F, Yiu KK, Merrouche W, Chan HL 2012 Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan. J Hepatol 56:833-839.
310. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M, Levstik M, Crotty P, Elkashab M 2012 Feasibility and diagnostic performance of the Fibroscan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 55:199-208.
311. Roulot D, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S, Le Clesiau H, BeaugrandM2011 Transient elastography as a screening tool for liver fibrosis and cir-rhosis in a community-based population aged over 45 years. Gut 60:977-984.
312. Palmeri ML, WangMH, Rouze NC, Abdelmalek MF, Guy CD, Moser B, Diehl AM, Nightingale KR 2011 Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 55:666-672.
313. Friedrich-RustM, RomenD, Vermehren J, Kriener S, Sadet D, Herrmann E, Zeuzem S, Bojunga J 2012 Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 81:e325-e331.
314. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL 2011 Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 259:749-756.
315. GuhaIN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM 2008 Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47:455-460.
316. Wieckowska A, Zein NN, Yerian LM, Lopez AR, Mc-Cullough AJ, Feldstein AE 2006 In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:27-33.
317. Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, KomatsuM, Nagaya T, Joshita S, UmemuraT, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Tanaka E, Sano K 2010 Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol 44:440-447.
318. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ 2009 Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50:1072-1078.
319. Pirola L, Balcerczyk A, Okabe J, El-Osta A 2010 Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 6:665-675.
320. Wong VW, Chan HL 2011 Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test? J Gastroenterol Hepatol 26:419-420.
321. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM 2009 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1677-1686.
322. The International Expert Committee 2009 International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327-1334.
323. American Diabetes Association 2012 Standards of medical care in diabetes-2012. Diabetes Care 35(Suppl 1):S11-S63.
324. Shiga T, Moriyoshi Y, Nagahara H, ShiratoriK2009 Nonalcoholic fatty liver is a risk factor for postprandial hyperglycaemia, but not for impaired fasting glucose. J Gastroenterol 44:757-764.
325. Koga M, Kasayama S 2010 Clinical impact of glycated albumin as another glycaemic control marker. Endocr J 57:751-762.
326. Cacciatore L, Cozzolino G, Giardina MG, De Marco F, Sacca L, Esposito P, Francica G, Lonardo A, MatarazzoM, Varriale A 1988 Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res 7:185-188.
327. Hojo M, Watanabe S 2011 Pharmacological therapy of nonalcoholic steatohepatitis. Hepatol Res 41:209-216.
328. Promrat K, Kleiner DE, NiemeierHM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR 2010 Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:121-129.
329. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA 2009 Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49:80-86.
330. Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D2011 Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs 16: 121-136.
331. Musso G, Cassader M, Rosina F, GambinoR2012 Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55:885-904.
332. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM 2010 Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 33:2156-2163.
333. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R 2011 Reversal of type 2 diabetes: normalisation of β cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54:2506-2514.
334. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F 2012 Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577-1585.
335. Dixon JB, Alberti G, Rubino F, Zimmet P 2011 Bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes: a position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Brussels: International Diabetes Federation.
336. Alamo M, Sepúlveda M, Gellona J, Herrera M, Astorga C, Manterola C 2012 Sleeve gastrectomy with jejunal bypass for the treatment of type 2 diabetes mellitus in patients with body mass index <35 kg/m2. A cohort study. Obes Surg 22:1097-1103.
337. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M 2010 Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 1:CD007340.
338. Weiner RA 2010 Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 28:274-279.
339. Dixon JB, Bhathal PS, O'Brien PE 2006 Weight loss and non-alcoholic fatty liver disease: falls in γ-glutamyl trans-ferase concentrations are associated with histologic improvement. Obes Surg 16:1278-1286.
340. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A, Romon M, Pattou F 2009 Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137: 532-540.
341. Miller GD, Nicklas BJ, FernandezA2011 Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 7:618-624.
342. Huang H, Kasumov T, Gatmaitan P, Heneghan HM, Kashyap SR, Schauer PR, Brethauer SA, Kirwan JP 2011 Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients. Obesity 19:2235-2240.
343. Appachi S, Kelly KR, Schauer PR, Kirwan JP, Hazen S, Gupta M, Kashyap SR 2011 Reduced cardiovascular risk following bariatric surgeries is related to a partial recovery from "adiposopathy." Obes Surg 21:1928-1936.
344. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, Simard S, Marceau P 2004 Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135:48-58.
345. Satapathy SK, Sanyal AJ 2010 Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab 21:668-675.
346. Ribeireiro T, Swain J, Sarr M, Kendrick M, Que F, Sanderson S, Krishnan A, Viker K, Watt K, Charlton M 2011 NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery-a prospective analysis. Obes Surg 21: 310-315.
347. Bonekamp S, Barone BB, Clark J, Stewart KJ 2008 The effect of an exercise training intervention on hepatic steatosis (Abstract 1119). Hepatology 48(Suppl 1):806A.
348. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J 2009 Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 50:68-76.
349. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, MooreS, Taylor R, DayCP, TrenellMI2011Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 60: 1278-1283.
350. Kawaguchi T, Shiba N, Maeda T, Matsugaki T, Takano Y, Itou M, Sakata M, Taniguchi E, Nagata K, SataM2011 Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: a pilot study. J Gastroenterol 46:746-757.
351. Rabøl R, Petersen KF, Dufour S, Flannery C, Shulman GI 2011 Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci USA 108:13705-13709.
352. Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, Kurita S, Arai K, Yamashita T, Sasaki M, Nakanuma Y, Kaneko S 2010 Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 33:284-286.
353. Wang P, Kang D, Cao W, Wang Y, Liu Z 2012 Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28: 109-122.
354. Currie CJ, Poole CD, Gale EAM 2009 The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777.
355. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller H 2012 Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55:1619-1632.
356. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG, Diabetes and Cancer Research Consortium 2012 Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55:1607-1618.
357. Nar A, Gedik O 2009 The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 46:113-118.
358. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA 2011 Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 54:1631-1639.
359. Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR 2010 Pioglitazone, but not metformin, reduces liver fat in type-2 diabetes mellitus independent of weight changes. J Diabetes Complications 24:289-296.
360. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H 2010 Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 32:1211-1221.
361. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, MurrayKF, Rosenthal P, AbramsSH, ScheimannAO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR 2011 Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305:1659-1668.
362. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F 2008 The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease in cyclin D1 level. Oncogene 27:3576-3586.
363. DonadonV, BalbiM, GhersettiM, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C 2009 Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 15:2506-2511.
364. HassanMM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN 2010 Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116:1938-1946.
365. Musso G, Gambino R, Cassader M, Pagano G 2010 A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52:79-104.
366. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J 2008 Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135:1176-1184.
367. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR 2010 Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675-1685.
368. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K 2006 A placebocontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297-2307.
369. Armstrong MJ, Houlihan DD, Rowe IA 2010 Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 363:1185; author reply 186.
370. Bloomgarden ZT 2011 Type 2 diabetes: uses of thiazolidinediones and insulin. Diabetes Care 34:e11-e16.
371. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA 298:1180-1188.
372. Kelly IE, Han TS, Walsh K, Lean MEJ 1999 Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22: 288-293.
373. Hernandez AV, Usmani A, Rajamanickam A, Moheet A 2011 Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebocontrolled randomized clinical trials. Am J Cardiovasc Drugs 11:115-128.
374. Nissen SE, Wolski K 2010 Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191-1201.
375. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA 2010 Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411-418.
376. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry Jr CP, VaughnDJ, Nessel L, Selby J, StromBL 2011 Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916-922.
377. Loke YK, Singh S, Furberg CD 2009 Long-term use of thiazolidinediones and fractures in type 2 diabetes: a metaanalysis. CMAJ 180:32-39.
378. Deacon CF 2011 Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13:7-18.
379. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL 2012 Effects of glucagon-like peptide-1 receptor agonists on weight loss: systemic review and meta-analyses of randomised controlled trials. BMJ 344:d7771.
380. Kenny PR, Brady DE, TorresDM, Ragozzino L, Chalasani N, Harrison SA 2010 Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 105:2707-2709.
381. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG 2008 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275-286.
382. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA 2011 GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE 6:e25269.
383. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S 2011 Glucagonlike peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54:1214-1223.
384. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, FregaGN, Benedetti A, Gastaldelli A 2011 Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 31:1285-1297.
385. Kim MK, Chae YN, Kim HD, Yang EK, Cho EJ, Choi SH, Cheong YH, Kim HS, Kim HJ, Jo YW, Son MH, Kim SH, Shin CY 2012 DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci 90:21-29.
386. Miyazaki M, Kato M, Tanaka K, Tanaka M, Kohjima M, Nakamura K, Enjoji M, Nakamuta M, Kotoh K, Takayanagi R 2012 Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Report 5:729-733.
387. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA 2010 Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51: 1584-1592.
388. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD 2012 Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 302:G762-G772.
389. Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH 2010 The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 30: 795-808.
390. ElashoffM, MatveyenkoAV, Gier B, Elashoff R, ButlerPC 2011 Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150-156.
391. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD 2011 Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 106: 71-77.
392. Arendt BM, Allard JP 2011 Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required? Am J Gastroenterol 106:78-80.
393. Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, DerosaG2012 Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol 24:164-171.
394. Nelson A, TorresDM, Morgan AE, Fincke C, Harrison SA 2009 A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebocontrolled trial. J Clin Gastroenterol 43:990-994.
395. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP 2011 Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 43:167-171.
396. Cohen DE, Anania FA, Chalasani N 2006 An assessment of statin safety by hepatologists. Am J Cardiol 97:77C-81C.
397. Zheng S, Hoos L, Cook J, Tetzloff G, Davis Jr H, van Heek M, Hwa JJ 2008 Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 584:118-124.
398. DeushiM, NomuraM, Kawakami A, HaraguchiM, ItoM, Okazaki M, Ishii H, YoshidaM2007 Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 581:5664-5670.
399. YoshidaM2011 Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe inNAFLD/NASHtreatment. Curr Vasc Pharmacol 9:121-123.
400. Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A 2010 Efficacy of ezetemibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 40:613-621.
401. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T 2011 Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 46:101-107.
402. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, MarzioniM, DeMinicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A 2006 A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferatoractivated receptor-α and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 169:846-860.
403. Basaranoglu M, Acbay O, Sonsuz A 1999 A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31:384.
404. Kallwitz ER, McLachlan A, Cotler SJ 2008 Role of peroxisome proliferator-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 14:22-28.
405. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGillDB 1996 Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23:1464-1467.
406. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, Takahashi M, Akisawa N, Iwasaki S, Oben JA, Onishi S 2007 Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45:1375-1381.
407. Georgescu EF 2008 Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Adv Ther 25:1141-1174.
408. Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Maeyama S, Saito S, Iwasaki T, Terauchi Y, Nakajima A 2007 Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 52:3455-3464.
409. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L 2009 Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 15:942-954.
410. Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, Koya D, Tsuneki H, Sasaoka T 2010 Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 151:2040-2049.
411. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C 2008 Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2:CD007176.
412. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C 2007 Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systemic review and meta-analysis. JAMA 297:842-857.
413. Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E 2005 Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:37-46.
414. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P 2004 Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39: 770-778.
415. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, RiviéreM, Spé-nard J 2011 A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 54:1011-1019.
416. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T 2010 High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52:472-479.
417. Haedrich M, Dufour JF 2011 UDCA for NASH: end of story? J Hepatol 54:856-858.
418. Pietu F, Guillaud O, Walter T, Vallin M, Hervieu V, Scoazec JY, Dumortier J 2012 Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol 36: 146-155.
419. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ 2011 Pentoxifylline improve nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54:1610-1619.
420. Schnabl B 2010 Peroxisome proliferator-activated receptor-δ as emerging target in liver disease. Drug Dev Res 71:106-111.
421. Musso G, Gambino R, Cassader M, Pagano G 2012 A novel approach to control hyperglycaemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systemic review and meta-analysis of randomized trials. Ann Med 44:375-393.
422. Schalkwijk CG, Miyata T 2012 Early-and advanced nonenzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids 42:1193-1204.
423. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A 2011 Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (de-PLAQUE): a randomised clinical trial. Lancet 378:1547-1559.
424. Candia R, Riquelme A, Baudrand R, CarvajalCA, Morales M, Solís N, Pizarro M, Escalona A, Carrasco G, Boza C, Pérez G, Padilla O, Cerda J, Fardella CE, Arrese M 2012 Overexpression of 11 β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver Int 32:392-399.
425. El-Serag HB 2011 Hepatocellular carcinoma. N Engl J Med 365:1118-1127.
426. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A 2011 Nonalcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128:2436-2443.